Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has secured marketing approval from China’s National Medical Products Administration (NMPA) for its Juvéderm product line, specifically the Juvéderm越致 dermal filler. This crosslinked sodium hyaluronate gel, which includes lidocaine for comfort during treatment, is designed for injection into the middle to deep layers of facial dermal tissue to effectively correct severe nasolabial folds.
The Juvéderm family of products, known for their advanced technology, has seen seven launches under Allergan Aesthetics’ umbrella. The lineup includes Ultra, Ultra Plus, and 越致, which utilize Hylacross technology, as well as Voluma, Volift, Volbella, and Volux, which employ Vycross technology. These products cater to a range of aesthetic concerns, including cheek augmentation, nasolabial fold correction, lip enhancement, nose and jawline contouring.
AbbVie’s acquisition of Allergan, an Irish pharmaceutical company, for $64.084 billion in May 2020 marked a significant expansion in the medical aesthetics sector. The integration of Allergan into AbbVie’s portfolio has since led to the rebranding of the aesthetics division as Allergan Aesthetics, reinforcing its commitment to innovation in the field.- Flcube.com
